{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:05:56Z","timestamp":1787969156164,"version":"build-2784847793"},"reference-count":71,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Marabio, Inc.","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Genetic and environmental factors during early development contribute to autism pathogenesis. Maternal autoantibodies recognizing specific fetal brain proteins can predict autism risk in a subset of cases. These antibodies cross the placenta and bind to their target antigens, which play critical roles in neurodevelopment, thereby increasing autism risk in this mechanistically defined subtype, Maternal Autoantibody-Related Autism (MARA). A multi-ELISA assay that detects maternal autoantibody combinations associated with increased autism risk has been described in the literature. This study aimed to transfer the MARA related autoantibody component assays to a clinical development laboratory for optimization and performance characterization. Methods: Indirect ELISA assays for eight maternal autoantibodies targeting LDH-A, LDH-B, GAH, STI1, CRMP-1, CRMP-2, NSE, and YB-1 were transferred from an academic laboratory to a clinical development laboratory for optimization and determination of the analytical performance and preliminary assay cutoff values. Standard methodologies were used to assess linearity, sensitivity, specificity, precision, and stability. Predefined validation protocols based on professional guidelines with established acceptance criteria for each parameter were followed. Results: Optimized ELISAs met the acceptable analytical performance criteria. All assays except one demonstrated excellent linearity when diluted with buffer or non-reactive plasma. The sensitivity analysis showed the lower limit of quantification discretely above the limit of detection, and below the preliminary population-based threshold values. Coefficients of variation for within-lot reproducibility of positive samples were &lt;15%, with two minor exceptions. Common interfering substances, except whole human IgG, did not affect assay performance. Microtiter assay plates were stable for at least six months without significant assay drift. Conclusions: These maternal autoantibody assays demonstrated high sensitivity, specificity, and robustness, supporting progression to validation in CLIA-certified clinical laboratories. These assays will enable rigorous clinical evaluation of the accuracy of specific antibody combinations previously reported in the peer reviewed literature to specifically correlate with autism.<\/jats:p>","DOI":"10.3390\/diagnostics16111665","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:06:56Z","timestamp":1780049216000},"page":"1665","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analytical Validation of an ELISA Assay for Maternal Autoantibody-Related Autism"],"prefix":"10.3390","volume":"16","author":[{"given":"Mags","family":"McInerney","sequence":"first","affiliation":[{"name":"MARAbio, Inc., Salt Lake City, UT 84101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Hurley","sequence":"additional","affiliation":[{"name":"Corgenix, Inc., Broomfield, CO 80020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Barkow","sequence":"additional","affiliation":[{"name":"Corgenix, Inc., Broomfield, CO 80020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Menning","sequence":"additional","affiliation":[{"name":"Corgenix, Inc., Broomfield, CO 80020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Nicolace","sequence":"additional","affiliation":[{"name":"Corgenix, Inc., Broomfield, CO 80020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Schauer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and UC Davis MIND Institute, University of California Davis, Sacramento, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-5875","authenticated-orcid":false,"given":"Judy","family":"Van de Water","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and UC Davis MIND Institute, University of California Davis, Sacramento, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0293-7676","authenticated-orcid":false,"given":"E. Robert","family":"Wassman","sequence":"additional","affiliation":[{"name":"MARAbio, Inc., Salt Lake City, UT 84101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.21037\/tp.2019.09.09","article-title":"Autism spectrum disorder: Definition, epidemiology, causes, and clinical evaluation","volume":"9","author":"Hodges","year":"2020","journal-title":"Transl. Pediatr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2040-2392-2-13","article-title":"Increased midgestational IFN-gamma, IL-4 and IL-5 in women bearing a child with autism: A case-control study","volume":"2","author":"Goines","year":"2011","journal-title":"Mol. Autism"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nurt.2010.05.003","article-title":"Immune dysfunction in autism: A pathway to treatment","volume":"7","author":"Careaga","year":"2010","journal-title":"Neurotherapeutics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.biopsych.2008.05.006","article-title":"Maternal mid-pregnancy autoantibodies to fetal brain protein: The early markers for autism study","volume":"64","author":"Croen","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molimm.2021.12.009","article-title":"Imbalance in pro-inflammatory and anti-inflammatory cytokines milieu in B cells of children with autism","volume":"141","author":"Nadeem","year":"2022","journal-title":"Mol. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cercor\/bhae082","article-title":"Differences in mid-gestational and early postnatal neonatal cytokines and chemokines are associated with patterns of maternal autoantibodies in the context of autism","volume":"34","author":"McLellan","year":"2024","journal-title":"Cereb. Cortex"},{"key":"ref_7","first-page":"226","article-title":"Autism: Maternally derived antibodies specific for fetal brain proteins","volume":"29","author":"Braunschweig","year":"2008","journal-title":"Neurotoxicology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/s41380-020-00998-8","article-title":"Risk assessment analysis for maternal autoantibody-related autism (MAR-ASD): A subtype of autism","volume":"26","author":"Becker","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1038\/tp.2013.50","article-title":"Autism-specific maternal autoantibodies recognize critical proteins in developing brain","volume":"3","author":"Braunschweig","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bbi.2017.12.014","article-title":"Identification of the antigenic epitopes of maternal autoantibodies in autism spectrum disorders","volume":"69","author":"Edmiston","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbi.2019.12.002","article-title":"Peptides of neuron specific enolase as potential ASD biomarkers: From discovery to epitope mapping","volume":"84","author":"Edmiston","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1038\/s41380-022-01633-4","article-title":"Maternal autoantibody profiles as biomarkers for ASD and ASD with co-occurring intellectual disability","volume":"27","author":"Croen","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/DBP.0000000000001100","article-title":"Pilot Study of Maternal Autoantibody-Related Autism","volume":"43","author":"Angkustsiri","year":"2022","journal-title":"J. Dev. Behav. Pediatr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1038\/tp.2013.47","article-title":"Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey","volume":"3","author":"Bauman","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jneuroim.2012.08.002","article-title":"Maternal autism-associated IgG antibodies delay development and produce anxiety in a mouse gestational transfer model","volume":"252","author":"Braunschweig","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbr.2014.02.045","article-title":"Embryonic intraventricular exposure to autism-specific maternal autoantibodies produces alterations in autistic-like stereotypical behaviors in offspring mice","volume":"266","author":"Camacho","year":"2014","journal-title":"Behav. Brain Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1038\/s41380-018-0126-1","article-title":"Autism-specific maternal autoantibodies produce behavioral abnormalities in an endogenous antigen-driven mouse model of autism","volume":"25","author":"Jones","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41380-023-02020-3","article-title":"Altered behavior, brain structure, and neurometabolites in a rat model of autism-specific maternal autoantibody exposure","volume":"28","author":"Bruce","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.neubiorev.2008.08.003","article-title":"Ultrasonic vocalizations: A tool for behavioural phenotyping of mouse models of neurodevelopmental disorders","volume":"33","author":"Scattoni","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ku, K.M., Weir, R.K., Silverman, J.L., Berman, R.F., and Bauman, M.D. (2016). Behavioral Phenotyping of Juvenile Long-Evans and Sprague-Dawley Rats: Implications for Preclinical Models of Autism Spectrum Disorders. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158150"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrn.2015.8","article-title":"Neurobiology of rodent self-grooming and its value for translational neuroscience","volume":"17","author":"Kalueff","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Saunders, N.R., Liddelow, S.A., and Dziegielewska, K.M. (2012). Barrier mechanisms in the developing brain. Front. Pharmacol., 3.","DOI":"10.3389\/fphar.2012.00046"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1113\/JP275376","article-title":"Physiology and molecular biology of barrier mechanisms in the fetal and neonatal brain","volume":"596","author":"Saunders","year":"2018","journal-title":"J. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41398-023-02335-3","article-title":"Maternal brain reactive antibodies profile in autism spectrum disorder: An update","volume":"13","author":"Spielman","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"792","DOI":"10.21037\/atm.2019.11.53","article-title":"Emerging biomarkers in autism spectrum disorder: A systematic review","volume":"7","author":"Frye","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1289\/ehp.8483","article-title":"The CHARGE study: An epidemiologic investigation of genetic and environmental factors contributing to autism","volume":"114","author":"Croen","year":"2006","journal-title":"Environ. Health Perspect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"113693","DOI":"10.1016\/j.jim.2024.113693","article-title":"How to verify the analytical and clinical performance of ELISA immunoanalysis in the real laboratory practice. PCSK9 as an example","volume":"530","author":"Vackova","year":"2024","journal-title":"J. Immunol. Methods"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cne.22157","article-title":"Developmental expression of prion protein and its ligands stress-inducible protein 1 and vitronectin","volume":"517","author":"Hajj","year":"2009","journal-title":"J. Comp. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11330","DOI":"10.1523\/JNEUROSCI.2313-05.2005","article-title":"Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways","volume":"25","author":"Lopes","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jneuroim.2011.08.008","article-title":"Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behcet\u2019s disease","volume":"239","author":"Vural","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"ref_31","first-page":"1457","article-title":"Hyperactivity and attention deficits in mice with decreased levels of stress-inducible phosphoprotein 1 (STIP1)","volume":"8","author":"Beraldo","year":"2015","journal-title":"Dis. Model. Mech."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.mcn.2003.11.006","article-title":"Involvement of collapsin response mediator proteins in the neurite extension induced by neurotrophins in dorsal root ganglion neurons","volume":"25","author":"Quach","year":"2004","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1385\/MN:28:1:51","article-title":"Collapsin response mediator proteins (CRMPs): Involvement in nervous system development and adult neurodegenerative disorders","volume":"28","author":"Charrier","year":"2003","journal-title":"Mol. Neurobiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12035-011-8166-4","article-title":"Collapsin response mediator protein-2: An emerging pathologic feature and therapeutic target for neurodisease indications","volume":"43","author":"Hensley","year":"2011","journal-title":"Mol. Neurobiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nn1179","article-title":"Cypin regulates dendrite patterning in hippocampal neurons by promoting microtubule assembly","volume":"7","author":"Akum","year":"2004","journal-title":"Nat. Neurosci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"15468","DOI":"10.1523\/JNEUROSCI.2442-11.2011","article-title":"The role of PSD-95 and cypin in morphological changes in dendrites following sublethal NMDA exposure","volume":"31","author":"Tseng","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/B978-0-12-416618-9.00006-6","article-title":"Measurement of enolase activity in cell lysates","volume":"542","author":"Fukano","year":"2014","journal-title":"Methods Enzymol."},{"key":"ref_38","first-page":"1402","article-title":"Y-box-binding protein 1 (YB-1) and its functions","volume":"76","author":"Eliseeva","year":"2011","journal-title":"Biochemistry"},{"key":"ref_39","unstructured":"Clinical and Laboratory Standards Institute (2026, March 02). CLSI EP17-A2 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline-Second Edition. Available online: https:\/\/mdcpp.com\/doc\/standard\/CLSIEP17-A2-2012.pdf."},{"key":"ref_40","unstructured":"American National Standards Institute (2026, March 02). CLSI EP05-A3 Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline\u2013Third Edition. Available online: https:\/\/mdcpp.com\/doc\/standard\/CLSIEP05-A3-2014.pdf."},{"key":"ref_41","unstructured":"Clinical and Laboratory Standards Institute (2026, March 02). CLSI EP07 Interference Testing in Clinical Chemistry\u2013Third Edition. Available online: https:\/\/blog.ansi.org\/ansi\/clsi-ep07-ed3-r2022-interference-testing-chemistry\/."},{"key":"ref_42","unstructured":"College of American Pathologists (2026, March 02). All Common CAP Accreditation Checklist. Available online: https:\/\/www.cap.org\/laboratory-improvement\/accreditation\/accreditation-checklists."},{"key":"ref_43","unstructured":"College of American Pathologists (2026, March 02). Chemistry and Toxicology CAP Accreditation Checklist. Available online: https:\/\/www.cap.org\/laboratory-improvement\/accreditation\/accreditation-checklists."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00401706.1969.10490657","article-title":"Procedures for Detecting Outlying Observations in Samples","volume":"11","author":"Grubbs","year":"1969","journal-title":"Technometrics"},{"key":"ref_45","unstructured":"NEQAS, U.K. (2026, May 19). Analytical versus Diagnostic Sensitivity and Specificity. Available online: https:\/\/www.immqas.org.uk\/news\/analytical-vs-clinical-sensitivity-and-specificity\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e213298","DOI":"10.1001\/jamapediatrics.2021.3298","article-title":"Effect of Preemptive Intervention on Developmental Outcomes Among Infants Showing Early Signs of Autism: A Randomized Clinical Trial of Outcomes to Diagnosis","volume":"175","author":"Whitehouse","year":"2021","journal-title":"JAMA Pediatr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaac.2015.12.014","article-title":"Prospective Longitudinal Studies of Infant Siblings of Children With Autism: Lessons Learned and Future Directions","volume":"55","author":"Szatmari","year":"2016","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jaac.2021.01.006","article-title":"The Ethics of Predicting Autism Spectrum Disorder in Infancy","volume":"60","author":"MacDuffie","year":"2021","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1007\/s10803-021-04900-5","article-title":"A Longitudinal Study of Language Trajectories and Treatment Outcomes of Early Intensive Behavioral Intervention for Autism","volume":"51","author":"Frazier","year":"2021","journal-title":"J. Autism Dev. Disord."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Brefort, E., Saint-Georges-Chaumet, Y., Cohen, D., and Saint-Georges, C. (2022). Two-year follow-up of 90 children with autism spectrum disorder receiving intensive developmental play therapy (3i method). BMC Pediatr., 22.","DOI":"10.1186\/s12887-022-03431-x"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Williamson, I.O., Elison, J.T., Wolff, J.J., and Runge, C.F. (2020). Cost-Effectiveness of MRI-Based Identification of Presymptomatic Autism in a High-Risk Population. Front. Psychiatry, 11.","DOI":"10.3389\/fpsyt.2020.00060"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e20011","DOI":"10.2196\/20011","article-title":"Coaching While Waiting for Autism Spectrum Disorder Assessment: Protocol of a Pilot Feasibility Study for a Randomized Controlled Trial on Occupational Performance Coaching and Service Navigation Support","volume":"10","author":"Bernie","year":"2021","journal-title":"JMIR Res. Protoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1542\/peds.2010-2825","article-title":"Recurrence risk for autism spectrum disorders: A Baby Siblings Research Consortium study","volume":"128","author":"Ozonoff","year":"2011","journal-title":"Pediatrics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13229-019-0300-6","article-title":"Reproductive stoppage in autism spectrum disorder in a population of 2.5 million individuals","volume":"10","author":"Larsson","year":"2019","journal-title":"Mol. Autism"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s13224-015-0813-7","article-title":"Correlation of Maternal Autoantibodies with Fetal Congenital Heart Block","volume":"66","author":"Madhusudan","year":"2016","journal-title":"J. Obstet. Gynaecol. India"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Lindroos, J.L.V., Bjork, M.H., and Gilhus, N.E. (2024). Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13041136"},{"key":"ref_57","first-page":"1637","article-title":"FcRn inhibitors: A novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMoa2314466","article-title":"Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn","volume":"391","author":"Moise","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMe2401020","article-title":"Inhibiting IgG in Hemolytic Disease of the Fetus","volume":"391","author":"Maisonneuve","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_60","unstructured":"Arumugham, V.B., and Rayi, A. (2026, March 02). NIH. National Library of Medicine. StatPearls. Intravenous Immunoglobulin (IVIG), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554446\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1038\/s41598-024-54423-z","article-title":"Intravenous immunoglobulin for patients with unexplained recurrent implantation failure: A 6-year single center retrospective review of clinical outcomes","volume":"14","author":"Peero","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"101527","DOI":"10.1016\/j.eclinm.2022.101527","article-title":"Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: A double-blind, randomised, placebo-controlled trial","volume":"50","author":"Yamada","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ajog.2024.03.044","article-title":"Intravenous immunoglobulin for the treatment of severe maternal alloimmunization: Individual patient data meta-analysis","volume":"231","author":"Mustafa","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41398-018-0214-7","article-title":"Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism","volume":"8","author":"Connery","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin","volume":"26","author":"Nimmerjahn","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Tjon, A.S., van Gent, R., Geijtenbeek, T.B., and Kwekkeboom, J. (2015). Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00197"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","article-title":"Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin","volume":"2","author":"Sultan","year":"1984","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Nagelkerke, S.Q., and Kuijpers, T.W. (2014). Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00674"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"15314","DOI":"10.1038\/ncomms15314","article-title":"Engineered clearing agents for the selective depletion of antigen-specific antibodies","volume":"8","author":"Devanaboyina","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/11\/1665\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:11:37Z","timestamp":1780287097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/11\/1665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":71,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["diagnostics16111665"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16111665","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}